文献速递鼻科

生物制剂治疗慢性鼻窦炎伴鼻息肉期间后嗅觉恢复的前瞻性纵向研究

Retronasal olfactory recovery during biologic therapy for chronic rhinosinusitis with nasal polyps: a prospective longitudinal study with parallel orthonasal assessment.
PubMed 文献 · Rhinology · 2026-10-30

本研究前瞻性纵向评估了重度慢性鼻窦炎伴鼻息肉患者接受生物制剂治疗后后嗅觉功能的恢复情况,并比较了IL-4/IL-13与IL-5通路阻断的差异。结果显示后嗅觉功能在4周内快速改善,且度普利尤单抗在後嗅觉功能和症状改善方面优于美泊利单抗。

要点

  • 生物制剂治疗可显著改善慢性鼻窦炎伴鼻息肉患者的前嗅觉和后嗅觉功能。
  • 后嗅觉功能在治疗4周内快速改善,可能作为早期反应标志物。
  • 度普利尤单抗(IL-4/IL-13阻断)在后嗅觉和症状改善上优于美泊利单抗。

核心结论

  • 生物制剂治疗可导致慢性鼻窦炎伴鼻息肉患者后嗅觉和前嗅觉的实质性恢复,且具有不同的时间动态。
  • 后嗅觉功能快速改善,可能对IL-4/IL-13阻断特别敏感,支持其作为生物制剂治疗反应的早期功能标志物的潜在作用。

研究设计与样本

  • 在基线及第4、12、24周进行评估,前嗅觉采用Sniffin' Sticks(TDI)测量,后嗅觉采用验证的20项识别测试。
  • 临床结局包括鼻息肉评分(NPS)、峰值鼻吸气流量和SNOT-22,采用重复测量方差分析评估纵向变化及时间-by-治疗交互作用。

主要发现

  • 基线时平均TDI为15.0,后嗅觉评分为7.2,表明严重损害。
  • 所有结局随时间显著改善,后嗅觉功能在4周内快速改善(从7.2升至10.4),TDI逐渐增加(24周时从15.0升至26.0)。
  • 在后嗅觉识别、TDI、SNOT-22和NPS上观察到显著的时间-by-治疗交互作用,表明恢复模式非平行,度普利尤单抗相比美泊利单抗与更大的后嗅觉功能和症状改善相关。

临床怎么用

  • 生物制剂治疗期间应关注后嗅觉功能的快速改善,可作为早期治疗反应的指标。
  • 对于重度慢性鼻窦炎伴鼻息肉患者,选择IL-4/IL-13阻断可能带来更优的后嗅觉和症状改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Olfactory dysfunction is a key feature of chronic rhinosinusitis with nasal polyps (CRSwNP). While biologics improve orthonasal olfaction, longitudinal data on retronasal function and differences between inflammatory targets remain limited. This study evaluated retronasal olfactory recovery over time during biologic therapy and compared IL-4/IL-13 versus IL-5 pathway blockade. METHODS: In this prospective longitudinal study, adults with severe CRSwNP starting biologics were assessed at baseline and after 4, 12, and 24 weeks. Orthonasal olfaction was measured using Sniffin' Sticks (TDI), and retronasal function with a validated 20-item identification test. Clinical outcomes included nasal polyp score (NPS), peak nasal inspiratory flow, and SNOT-22. Repeated-measures ANOVA was used to evaluate longitudinal changes and time-by-treatment interactions. RESULTS: Sixty-nine patients were included (44 dupilumab, 25 mepolizumab). At baseline, mean TDI was 15.0 and retronasal score 7.2, indicating severe impairment. All outcomes improved significantly over time. Retronasal function improved rapidly within 4 weeks (7.2 to 10.4). TDI increased progressively (15.0 to 26.0 at 24 weeks). Significant time-by-treatment interactions were observed for retronasal identification, TDI, SNOT-22, and NPS, indicating non-parallel recovery patterns with dupilumab being associated with greater improvements in retronasal function and symptoms compared with mepolizumab. CONCLUSIONS: Biologic therapy leads to substantial recovery of both retronasal and orthonasal olfaction in CRSwNP, with distinct considetemporal dynamics. Retronasal function shows rapid improvement and may be particularly sensitive to IL-4/IL-13 blockade, supporting its potential role as an early functional marker of response to biologic therapy.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Boscolo-Rizzo, Raimondo, Spinato, et al. Retronasal olfactory recovery during biologic therapy for chronic rhinosinusitis with nasal polyps: a prospective longitudinal study with parallel orthonasal assessment. Rhinology. 2026. PMID: 42958882. doi:10.4193/Rhin26.216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。